National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Filgotinib (Jyseleca®) HTA ID:21048

Filgotinib (Jyseleca®) is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

NCPE Assessment Process Complete
Rapid review commissioned 01/11/2021
Rapid review completed 10/12/2021
Rapid Review outcome A full HTA is not recommended. The NCPE recommends that filgotinib not be considered for reimbursement at the submitted price*.

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.